Incidence, severity, duration, and treatment of cutaneous adverse events in the DECIDE study of daclizumab HYP versus intramuscular interferon beta-1a in patients with relapsing-remitting multiple sclerosis

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2015
This article has no abstract
Epistemonikos ID: 3e9dd44f8142d65846573d98bc57c7ebd0e1154e
First added on: Apr 30, 2026